Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

The main objectives of the open label dosing and dosimetry study are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In both ongoing clinical trials, Cotara is delivered using convection-enhanced delivery (CED), a method developed by the U.S. National Institutes of Health that targets the specific tumor site in the brain.

"We believe the data generated from this dosimetry trial will be an important and necessary part of our Cotara regulatory package as we continue to advance the program," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "The trial design the regulatory authorities asked us to implement was necessarily complex and therefore challenging to enroll, requiring a significant commitment from both patients and the participating health care institutions. We are grateful for their successful efforts and our plan is now to expand the ongoing 40-patient Phase II Cotara GBM trial to these clinical sites, which should help expedite timely completion of the ongoing Phase II clinical trial."

Interim data from the dosimetry trial presented at the Society of Nuclear Medicine 2009 Annual Meeting in June showed that in patients dosed in the first two cohorts of the study, the concentration of Cotara in brain tumors was on average more than 300-fold higher than in other normal organs. In addition, these patients had all either met or exceeded the expected median survival time for recurrent GBM patients. Interim data from a Phase II study of GBM patients who have experienced a first relapse was presented at the XIV World Congress of Neurological Surgery in September. It highlighted a subset of 10 GBM patients and included follow-up durations ranging from seven weeks to over 73 weeks, showing an interim median recurrence-free
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is ... work, ImmunXT, their Immune System enhancement supplement, has,been ... as of March 2008.,ImmunXT has been proclaimed as ... ImmunXT (US Patent #7,205,284 B2),is a bio-active Micro-algae ...
... (OTC Bulletin Board: GNTA) announced today that it ... (FINRA, formerly,the NASD) has cleared a market maker,s ... the Over-the-Counter Bulletin Board (OTCBB). As a,result, the ... Company,s,common stock will begin on Wednesday, May 7, ...
... Calif., May 6 Kosan Biosciences,Incorporated (Nasdaq: ... Vice,President, Corporate Communications, will present at the Leerink ... the Grand Hyatt Hotel on,Friday, May 9, 2008 ... the presentation,can be accessed through http://www.wsw.com/webcast/leerink15/kosn/ ., ...
Cached Biology Technology:LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference 2
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... gene therapy reversed course of disease in mouse modelsIn ... disease, scientists were able to reverse the rodents' memory ... is crucial for the development of Alzheimer's disease. , ... that stopping the synthesis of a protein that is ...
... Billions of people tuned into recent Live 8 concert ... the altruistic cause spearheaded by former Boomtown Rat, Sir ... of us look out for each other, while others ... natural selection has designed individuals to behave selfishishly; selfish ...
... medically important fungus, causing potentially life-threatening infections in patients ... cause of respiratory allergy, and it is implicated in ... to lack the ability to reproduce sexually, but new ... the fungus has a number of characteristics of sex. ...
Cached Biology News:Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 2Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 3Helping in a selfish world 2Secret sex life of killer fungus? 2
Recombinant Rat Leptin, CF...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
... 25 mL pipets ,Angled acrylic pipet rack offers ... or round pipet cans. Constructed of 6 mm (1/4 ... W x 76 mm H x 289 mm D ... 89 mm W x 406 mm H x 292 ...
... Contact Printing Kit contains choice of PDMS ... of 100 / 200 micron squares or ... um x 10 mm lines, 3 PDMS ... or 60 nm and pitch of 400 ...
Biology Products: